BRAF and melanoma: New drugs targeting the MAPK pathway have produced excellent clinical responses in melanoma treatment, from the discovery of BRAF mutations in melanoma in 2002 to the FDA’s approval of the first BRAF inhibitor, vemurafenib, for melanoma treatment in 2011, therapies targeting the MAPK pathway have proven effective in less than a decade (Cheng et al., 2013).